Mankind Pharma Q3FY26 Results: Standalone Revenue ₹2,632.68 Cr, Net Profit ₹449.47 Cr
Mankind Pharma reported Q3FY26 standalone revenue of ₹2,632.68 crore and net profit of ₹449.47 crore. For the nine months ended December 31, 2025, standalone revenue was ₹7,839.36 crore with a net profit of ₹1,329.04 crore. The company's Board of Directors approved these unaudited financial results on February 3, 2026.
The announcement of quarterly financial results is a material event for investors and stakeholders, impacting investment decisions and company valuation.
The financial results show strong revenue and profit figures for the quarter and nine-month period, indicating positive business performance.
Mankind Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results at a meeting held on February 3, 2026, which commenced at 3:00 p.m. IST and concluded at 3:45 p.m. IST.
For the quarter ended December 31, 2025, the standalone revenue from operations stood at ₹2,632.68 crore. The profit for the period from continuing operations was ₹449.47 crore, with total comprehensive income at ₹452.53 crore. Basic Earnings Per Share (EPS) from continuing operations was ₹10.89 (not annualized).
In the nine months ended December 31, 2025, the standalone revenue from operations reached ₹7,839.36 crore. The profit for this period from continuing operations was ₹1,329.04 crore, and total comprehensive income was ₹1,349.21 crore. Basic EPS from continuing operations was ₹32.20 (not annualized).
The company also reported consolidated financial results. The auditors, M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., have issued an unmodified conclusion on both the standalone and consolidated financial results.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.